Development of bladder dysfunction in a rat model of dopaminergic brain lesion

Neurourology and Urodynamics

Volumn 30, Issue 1, 2011, Pages 188-193

  Soler, Roberto ^a,b   Füllhase, Claudius ^a,c   Santos, Cesar ^a   Andersson, Karl Erik ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

6 hydroxydopamine; bladder dysfunction; Parkinson's disease

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CAPACITY; BLADDER COMPLIANCE; BLADDER DYSFUNCTION; BRAIN DAMAGE; CONTROLLED STUDY; CYSTOMETRY; DOPAMINERGIC BRAIN LESION; FEMALE; NONHUMAN; OVERACTIVE BLADDER; PARAMETER; RAT; URINARY FREQUENCY; URINE VOLUME; URODYNAMICS;

ADRENERGIC AGENTS; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; MEDIAL FOREBRAIN BUNDLE; MICROINJECTIONS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; URINARY BLADDER, NEUROGENIC; URINATION; URODYNAMICS;

EID: 78651105004     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20917     Document Type: Article

References (25)

1. Dauer W, Przedborski S,. Parkinson's disease: Mechanisms and models. Neuron 2003; 39: 889-909.
2. Lees AJ, Hardy J, Revesz T,. Parkinson's disease. Lancet 2009; 373: 2055-66.
3. Sakakibara R, Uchiyama T, Yamanishi T, et al. Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm 2008; 115: 443-60.
4. Sammour ZM, Gomes CM, Barbosa ER, et al. Voiding dysfunction in patients with Parkinson's disease: Impact of neurological impairment and clinical parameters. Neurourol Urodyn 2009; 28: 510-5.
5. Araki I, Kitahara M, Oida T, et al. Voiding dysfunction and Parkinson's disease: Urodynamic abnormalities and urinary symptoms. J Urol 2000; 164: 1640-3.
6. Fowler CJ,. Update on the neurology of Parkinson's disease. Neurourol Urodyn 2007; 26: 103-9.
7. Seki S, Igawa Y, Kaidoh K, et al. Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn 2001; 20: 105-13.
8. Yoshimura N, Kuno S, Chancellor MB, et al. Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway. Br J Pharmacol 2003; 139: 1425-32.
9. Breese GR, Knapp DJ, Criswell HE, et al. The neonate-6-hydroxydopamine- lesioned rat: A model for clinical neuroscience and neurobiological principles. Brain Res Brain Res Rev 2005; 48: 57-73.
10. Stromberg I, Bjorklund H, Dahl D, et al. Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry. Brain Res Bull 1986; 17: 225-36.
11. Iancu R, Mohapel P, Brundin P, et al. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005; 162: 1-10.
12. Kitta T, Matsumoto M, Tanaka H, et al. GABAergic mechanism mediated via D receptors in the rat periaqueductal gray participates in the micturition reflex: An in vivo microdialysis study. Eur J Neurosci 2008; 27: 3216-25.
13. Rosin B, Nevet A, Elias S, et al. Physiology and pathophysiology of the basal ganglia-thalamo-cortical networks. Parkinsonism Relat Disord 2007; 13: S437-9.
14. Crossman AR,. Functional anatomy of movement disorders. J Anat 2000; 196: 519-25.
15. Winge K, Friberg L, Werdelin L, et al. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease. Eur J Neurol 2005; 12: 842-50.
16. Sakakibara R, Hattori T, Uchiyama T, et al. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 2001; 71: 600-6.
17. Truong L, Allbutt HN, Coster MJ, et al. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions. Brain Res Bull 2009; 78: 91-6.
18. Kim JH, Auerbach JM, Rodriguez-Gomez JA, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002; 418: 50-6.
19. Androutsellis-Theotokis A, Rueger MA, Park DM, et al. Targeting neural precursors in the adult brain rescues injured dopamine neurons. Proc Natl Acad Sci USA 2009; 106: 13570-5.
20. Przedborski S, Levivier M, Jiang H, et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995; 67: 631-47.
21. Yuan H, Sarre S, Ebinger G, et al. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J Neurosci Methods 2005; 144: 35-45.
22. Zuch CL, Nordstroem VK, Briedrick LA, et al. Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion. J Comp Neurol 2000; 427: 440-54.
23. Uhl GR, Hedreen JC, Price DL,. Parkinson's disease: Loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 1985; 35: 1215-8.
24. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-34.
25. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.